# ACP-101

Type: Technology

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/acp-101
Canonical HTML page: https://gethealthbrief.com/entity/acp-101

## Timeline

- **2024-12-31**: Fiscal Milestone — ACADIA reports record quarterly revenue and achieves annual GAAP profitability.
- **2024-03-11**: Trial Setback — Phase 3 ADVANCE-2 trial for pimavanserin in schizophrenia fails to meet primary endpoint.
- **2023-04-15**: Commercial Launch — Daybue officially enters the U.S. market with strong initial uptake.
- **2023-03-10**: FDA Approval — Daybue (trofinetide) approved as the first treatment for Rett syndrome.

## Recent coverage (1 stories)

### ACADIA Pharmaceuticals Q4 Earnings: Rare Disease Pivot Drives Record Growth
2026-02-27 12:47:29 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

ACADIA Pharmaceuticals reported a transformative fourth quarter, highlighted by the rapid commercial expansion of Daybue for Rett syndrome and the steady performance of Nuplazid. The company has successfully achieved GAAP profitability, signaling a robust shift toward a diversified rare disease and neurology portfolio.
Full story: https://gethealthbrief.com/story/acadia-pharmaceuticals-q4-earnings-rare-disease-growth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.